Patient perceptions of the efficacy and safety of tirzepatide: Discrepancies with clinical data and limited awareness of cardiovascular benefits
Представления пациентов об эффективности и безопасности тирзепатида: расхождения с клиническими данными и недостаточная осведомленность о сердечно-сосудистых преимуществах
2026-06-19
SCID: 54.1/j6u324xn
Discuss with AI
GIP/GLP-1 receptor agonistmajor adverse cardiovascular eventspatient perceptionstirzepatideweight loss
Figures from the paper
Abstract (AI)
Introduction The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide is a novel incretin-based medication that can effectively treat obesity, type 2 diabetes, and cardiometabolic disease. With the growing obesity epidemic in the USA, patients are increasingly discussing the role of the GIP/GLP-1RA with clinicians. Objective Patient perceptions prior to GIP/GLP-1RA agonist initiation remain unclear. This single-center, prospective, cross-sectional survey study assessed the baseline patient understanding of the efficacy and safety of tirzepatide. Methods One hundred and one patients not previously on GLP-1 or GIP/GLP-1 agonists who self-expressed interest in tirzepatide completed a brief survey at a multi-provider cardiology practice. Results Patients estimated an average weight loss of 17.38%, similar to the pooled mean of 17.73% from the SURMOUNT-1 and SURMOUNT-2 trials. The perceived side effect rate (36.68%) was substantially lower than trial-reported rates (78.14%), while the perceived discontinuation rate (15.45%) exceeded reported values (5.72%). Patients also estimated a relative weight rebound of 15.00%, which was markedly lower than the 53.32% observed in the SURMOUNT-4 trial. Finally, only 27.70% of the patients perceived tirzepatide as likely to reduce the risk of major adverse cardiovascular events (MACE-3; nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death). Conclusion These results highlight discrepancies between patient perceptions and clinical data, revealing gaps in understanding tirzepatide’s efficacy and safety profile. Improved patient education and guidance may improve patient confidence, treatment adherence, and clinical outcomes.
Key Findings
1
In a survey of 101 interested patients, estimated tirzepatide weight loss averaged 17.38%, closely matching the 17.73% pooled clinical-trial result.
2
Only 27.70% of patients believed tirzepatide would likely reduce major adverse cardiovascular events, indicating limited awareness of cardiovascular benefits.
3
Patients markedly underestimated weight regain after treatment, estimating 15.00% versus 53.32% observed after withdrawal in SURMOUNT-4.
4
Patients overestimated treatment discontinuation, estimating 15.45% compared with the reported 5.72%.
5
Patients substantially underestimated side-effect frequency, reporting 36.68% versus 78.14% in clinical trials.
Research Object
Patients interested in initiating tirzepatide who had not previously used GLP-1 or GIP/GLP-1 agonists
Research Subject
Baseline patient perceptions and understanding of tirzepatide’s efficacy, safety, weight regain, and cardiovascular benefits compared with clinical data
Publication Details
Publication Date
2026-06-19
Journal
Publisher
ISSN
Cited by
0
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai6
Once-Weekly Semaglutide in Adults with Overweight or Obesity2021
Tirzepatide Once Weekly for the Treatment of Obesity2022
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity2023
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes2025
What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK2025